Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The U.S. Food and Drug Administration announced on 29 June that it selected seven participants for its PreCheck Pilot Program, which is designed to support new domestic pharmaceutical manufacturing facilities.
The selected companies are Amneal Pharmaceutical, Cellares Corp., Eli Lilly and Company, FUJIFILM Biotechnologies, Kriya Therapeutics, Kyowa Kirin, and Regeneron Pharmaceuticals. The listed facilities cover sterile liquid products, cell-based gene therapies, drug substance, commercial-scale cell culture biomanufacturing, AAV-based gene therapies and biotechnology drug substance.
FDA says participants will use a two-phase model: facility-readiness guidance before operations begin, followed by application-submission engagement intended to support earlier facility evaluation and inspections.
Sourcing note: The participant list, program structure and June 29 announcement are confirmed by FDA. Assertions that the pilot will reduce delays, strengthen resilience or improve access are FDA policy expectations and will need later evidence.
Why It Matters
Medicine supply-chain resilience is becoming a regulatory issue, not just an industrial one. Earlier FDA engagement may reduce avoidable manufacturing-review problems, but it also places agency capacity and selection criteria under closer scrutiny.
What to Watch
Watch whether the selected facilities reach application submission, whether FDA reports inspection timing or deficiency outcomes, and whether the pilot becomes a standing pathway for domestic drug and biologics manufacturing.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDADrug ManufacturingSupply ChainBiologicsPharmaceuticals